Stealth Polycyanoacrylate Nanoparticles as Tumor Necrosis Factor-.ALPHA. Carriers: Pharmacokinetics and Anti-tumor Effects.

Li, Yaping; Pei, Yuanying; Zhou, Zhao‐Hui; Zhang, Xianying; Gu, Zhou-Hui; Ding, Jian; Zhou, Jianjun; Gao, Xiu-Jian; Zhu, Jiaan

doi:10.1248/bpb.24.662

Cited by 37 publications

(13 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surface modification of poly( n -butyl cyanoacrylate) nanoparticles with polysorbate 80 (a nonionic surfactant and emulsifier derived from polyethoxylated sorbitan oleate, commercially available under the trade name Tween 80) proved to cross the blood brain barrier in vivo [149]. Thanks to their high resistance and ability to deliver drugs to RES organs [150], other cyanoacrylic polymers such as poly( n -hexadecyl cyanoacrylate) [151] and poly(methoxypoly(ethylene glycol) cyanoacrylate- co - n -hexadecyl cyanoacrylate) [152,153,154,155] have been used for the preparation of nanoparticles.…”

Section: Nanocarriersmentioning

confidence: 99%

Targeted Delivery of Protein Drugs by Nanocarriers

2010

View full text Add to dashboard Cite

Recent advances in biotechnology demonstrate that peptides and proteins are the basis of a new generation of drugs. However, the transportation of protein drugs in the body is limited by their high molecular weight, which prevents the crossing of tissue barriers, and by their short lifetime due to immuno response and enzymatic degradation. Moreover, the ability to selectively deliver drugs to target organs, tissues or cells is a major challenge in the treatment of several human diseases, including cancer. Indeed, targeted delivery can be much more efficient than systemic application, while improving bioavailability and limiting undesirable side effects. This review describes how the use of targeted nanocarriers such as nanoparticles and liposomes can improve the pharmacokinetic properties of protein drugs, thus increasing their safety and maximizing the therapeutic effect.

show abstract

Section: Nanocarriersmentioning

confidence: 99%

Targeted Delivery of Protein Drugs by Nanocarriers

2010

View full text Add to dashboard Cite

show abstract

“…Stealth nanoparticles (NP) are characterized by a prolonged halflife in the blood compartment that allows them to extravasate and accumulate more in pathological sites, such as tumors with leaky vasculature caused by the "enhanced permeability and retention effect" [3,4] . In our previous study, higher intratumoral drug accumulation and antitumor potency were achieved for recombinant human tumor necrosis factor-alpha (rHuTNF-α)-loaded stealth poly (methoxypolyethyleneglycol cyanoacrylate-co-n-hexadecyl cyanoacrylate) (PEG-PHDCA) NP with sizes of approximately 150 nm and methoxypolyethyleneglycol (MePEG) molecular weight of 5000 [5] . It is known that surface properties, particle size, and drug release behavior are the key for the biological fate of stealth NP.…”

Section: Introductionmentioning

confidence: 99%

Effect of MePEG molecular weight and particle size on in vitro release of tumor necrosis factor-alpha-loaded nanoparticles1

Fang

Shi

Pei

2005

Acta Pharmacologica Sinica

Self Cite

View full text Add to dashboard Cite

Aim: To study the in vitro release of recombinant human tumor necrosis factor‐alpha (rHuTNF‐α) encapsulated in poly (methoxypolyethyleneglycol cyanoacrylate‐co‐n‐hexadecyl cyanoacrylate) (PEG‐PHDCA) nanoparticles, and investigate the influence of methoxypolyethyleneglycol (MePEG) molecular weight and particle size. Methods: Three sizes (approximately 80, 170, and 240 nm) of PEGPHDCA nanoparticles loading rHuTNF‐α were prepared at different MePEG molecular weights (Mr=2000, 5000, and 10 000) using the double emulsion method. The in vitro rHuTNF‐α release was studied in PBS and rat plasma. Results: A higher burst‐release and cumulative‐release rate were observed for nanoparticles with higher MePEG molecular weight or smaller particle size. A decreased cumulative release of rHuTNF‐α following the initial burst effect was found in PBS, while the particle sizes remained constant and MePEG liberated. In contrast, in rat plasma, slowly increased cumulative‐release profiles were obtained after the burst effect. During a 5‐h incubation in rat plasma, more than 50% of the PEGPHDCA nanoparticles degraded. Conclusion: The MePEG molecular weight and particle size had an obvious influence on rHuTNF‐α release. rHuTNF‐α released from PEG‐PHDCA nanoparticles in a diffusion‐based pattern in PBS, but in a diffusion and erosion‐controlled manner in rat plasma.

show abstract

“…Other studies have also revealed that poly(methoxypolyethyleneglycol cyanoacrylate-co-n-hexadecylcyanoacrylate) NPs could enhance the half-life of TNF-α in tumor bearing mice along with the targeting efficiency and antitumor potency [60]. The increased antitumor activity might arise from the higher accumulation of nanotherapeutics in tumor tissues and longer plasma circulation time.…”

Section: Polymeric Nanocarriersmentioning

confidence: 99%

Engineering the Nanoparticle-Protein Interface for Cancer Therapeutics

Saie

Ray

Rotello

2015

Cancer Treatment and Research

View full text Add to dashboard Cite

Intracellular delivery of functional proteins using nanoparticles can be a game-changing approach for cancer therapy. However, cytosolic release of functional protein is still a major challenge. In addition, formation of protein corona on the surface of the nanoparticles can also alter the behavior of the nanoparticles. Here, we will review recent strategies for protein delivery into the cell. Finally we will discuss the issue of protein corona formation in light of nanoparticle-protein interactions.

show abstract

Stealth Polycyanoacrylate Nanoparticles as Tumor Necrosis Factor-.ALPHA. Carriers: Pharmacokinetics and Anti-tumor Effects.

Cited by 37 publications

References 26 publications

Targeted Delivery of Protein Drugs by Nanocarriers

Targeted Delivery of Protein Drugs by Nanocarriers

Effect of MePEG molecular weight and particle size on in vitro release of tumor necrosis factor-alpha-loaded nanoparticles1

Engineering the Nanoparticle-Protein Interface for Cancer Therapeutics

Contact Info

Product

Resources

About